Lenvatinib

Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.[1] Contents 1 Medical uses 2 Adverse effects 3 Interactions 4 Pharmacology 4.1 Mechanism of action 4.2 Pharmacokinetics 5 Chemistry 6 History 7 Brand names 8 References 9 External links ... [wikipedia]